Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.67 |
| ▸ | AXL | P30530 | 10/20 | 0.67 |
| ▸ | KDR | P35968 | 6/20 | 0.67 |
| ▸ | MERTK | Q12866 | 6/20 | 0.63 |
| ▸ | RET | P07949 | 4/20 | 0.58 |
| ▸ | KIT | P10721 | 4/20 | 0.58 |
| ▸ | FLT3 | P36888 | 4/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453538 | 1.00 | MET (0.67) | METAXLKDRMERTKRET | |
| Hydrochloric Acid SCHEMBL22749961 | 0.99 | MET (0.66) | METAXLKDRMERTKRET | |
| Hydrochloric Acid SCHEMBL29453840 | 0.99 | MET (0.66) | METAXLKDRMERTKRET | |
| Hydrochloric Acid SCHEMBL29453841 | 0.99 | MET (0.66) | METAXLKDRMERTKRET | |
| SCHEMBL22749893 | 0.91 | MET (0.56) | METAXLKDRMERTKRET | |
| SCHEMBL29453534 | 0.91 | MET (0.56) | METAXLKDRMERTKRET | |
| SCHEMBL22750269 | 0.91 | AXL (0.69) | METAXLKDRMERTKRET | |
| SCHEMBL29453561 | 0.91 | AXL (0.69) | METAXLKDRMERTKRET | |
| Hydrochloric Acid SCHEMBL22750226 | 0.90 | AXL (0.68) | METAXLKDRMERTKRET | |
| Hydrochloric Acid SCHEMBL29453827 | 0.90 | AXL (0.68) | METAXLKDRMERTKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-12-23 | — | — | US | claimed |
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-02-09 | — | — | US | claimed |
| EP-3980404-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-114040912-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2020247418-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-12-10 | — | — | WO | claimed |
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2020247418-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | MAP3K20, MAP3K6, MAP3K1 | MET 668/4885AXL 946/4885KDR 1167/4885 |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, PTK2B | MET 105/4885AXL 148/4885KDR 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.